MX2018000239A - Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. - Google Patents

Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Info

Publication number
MX2018000239A
MX2018000239A MX2018000239A MX2018000239A MX2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A
Authority
MX
Mexico
Prior art keywords
formula
hbed
radiometal
bisphosphonates
conjugates
Prior art date
Application number
MX2018000239A
Other languages
English (en)
Inventor
F Kung Hank
Rye Choi Seok
Wu Zehui
Ploessl Karl
Zha Zhihao
Original Assignee
Five Eleven Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Eleven Pharma Inc filed Critical Five Eleven Pharma Inc
Publication of MX2018000239A publication Critical patent/MX2018000239A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la formula I o formula II que son agentes de toma de imágenes óseas potenciales; ciertos compuestos etiquetados con 68Ga mostraron excelente captación y retención ósea; la presente invención también se refiere a composiciones farmacéuticas que comprenden un portador farmacéuticamente aceptable y un compuesto de formula I o formula II o una sal farmacéuticamente aceptable del mismo.(ver formula I y formula II).
MX2018000239A 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. MX2018000239A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US201662320296P 2016-04-08 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (1)

Publication Number Publication Date
MX2018000239A true MX2018000239A (es) 2018-05-23

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000239A MX2018000239A (es) 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Country Status (13)

Country Link
US (1) US10253052B2 (es)
EP (1) EP3319643B1 (es)
JP (1) JP6792875B2 (es)
KR (1) KR102651945B1 (es)
CN (1) CN107847618B (es)
AU (1) AU2016289474C1 (es)
CA (1) CA2991498A1 (es)
DK (1) DK3319643T3 (es)
EA (1) EA201890221A1 (es)
HK (1) HK1254864A1 (es)
IL (1) IL256726A (es)
MX (1) MX2018000239A (es)
WO (1) WO2017007790A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651945B1 (ko) 2015-07-07 2024-03-26 파이브 일레븐 파마 인크. Hbed-비스포스포네이트, 이의 방사성금속 접합체 및 이의 진단치료제로서의 용도
WO2018160544A1 (en) * 2017-03-02 2018-09-07 Five Eleven Pharma Inc. Radiopharmaceutical labeling device
US11723992B2 (en) * 2018-08-03 2023-08-15 Board Of Regents, The University Of Texas System Method for extraction and purification of 68GA
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
AU2020262961A1 (en) * 2019-04-26 2021-12-16 Five Eleven Pharma Inc. Prostate-specific membrane antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutic agents
US20230001027A1 (en) * 2019-10-01 2023-01-05 City Of Hope Metal chelating agents and methods of using the same
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329623T1 (de) * 2001-10-22 2006-07-15 Dow Global Technologies Inc Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
CN1826331A (zh) 2003-04-03 2006-08-30 塞马福尔药业公司 Pi－3激酶抑制剂前药
US7161000B2 (en) * 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP3466928A1 (en) * 2007-06-26 2019-04-10 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
EP2468760B1 (en) * 2009-08-20 2014-10-01 Fujifilm RI Pharma Co., Ltd. Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide
US9212335B2 (en) * 2011-04-13 2015-12-15 Firmenich Sa Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102651945B1 (ko) 2015-07-07 2024-03-26 파이브 일레븐 파마 인크. Hbed-비스포스포네이트, 이의 방사성금속 접합체 및 이의 진단치료제로서의 용도

Also Published As

Publication number Publication date
JP6792875B2 (ja) 2020-12-02
IL256726A (en) 2018-03-29
DK3319643T3 (da) 2020-06-15
EA201890221A1 (ru) 2018-06-29
CN107847618A (zh) 2018-03-27
WO2017007790A1 (en) 2017-01-12
AU2016289474B2 (en) 2020-12-24
KR102651945B1 (ko) 2024-03-26
WO2017007790A9 (en) 2018-01-04
US10253052B2 (en) 2019-04-09
KR20180026736A (ko) 2018-03-13
JP2018524352A (ja) 2018-08-30
CN107847618B (zh) 2021-07-16
EP3319643A1 (en) 2018-05-16
EP3319643A4 (en) 2019-04-10
EP3319643B1 (en) 2020-04-22
AU2016289474C1 (en) 2021-04-08
HK1254864A1 (zh) 2019-07-26
CA2991498A1 (en) 2017-01-12
AU2016289474A1 (en) 2018-02-01
US20170022224A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX2022010703A (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
UA118261C2 (uk) Хімічні сполуки
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12018500852A1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
WO2013040227A3 (en) Therapeutic compounds
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
TR201819805T4 (tr) Flavaglin türevleri̇.

Legal Events

Date Code Title Description
FG Grant or registration